Comparative Pharmacology
Head-to-head clinical analysis: CHOLOGRAFIN MEGLUMINE versus FERIDEX I V.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHOLOGRAFIN MEGLUMINE versus FERIDEX I V.
CHOLOGRAFIN MEGLUMINE vs FERIDEX I.V.
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cholografin meglumine is an iodinated contrast agent that opacifies the biliary tract. It is actively taken up by hepatocytes and excreted into the bile, allowing radiographic visualization of the bile ducts and gallbladder.
FERIDEX I.V. (ferumoxytol) is an iron oxide nanoparticle coated with a carbohydrate shell. After intravenous administration, ferumoxytol is taken up by macrophages of the reticuloendothelial system, releasing iron into the intracellular iron pool. Iron is transported by transferrin to erythroid precursor cells for hemoglobin synthesis, thereby replenishing iron stores.
Intravenous: 20 mL (10.3 g) of a 52% solution (meglumine salt) administered by slow IV injection over 3-5 minutes; repeated once after 10-15 minutes if visualization is inadequate, not to exceed 40 mL total.
15 mg/kg intravenous infusion over 4 hours, maximum single dose 1200 mg, repeat after 72 hours if ferritin <100 ng/mL and transferrin saturation <20%.
None Documented
None Documented
Terminal elimination half-life is approximately 1-2 hours in patients with normal hepatic function, reflecting rapid biliary excretion; prolonged in hepatic impairment.
Terminal elimination half-life (t½) of ferric carboxymaltose is approximately 7-12 hours (mean ~9 hours) in iron-deficient patients. Clinical context: The iron is rapidly delivered to the reticuloendothelial system for processing; reticulocyte response is seen within 1-2 weeks. The half-life reflects clearance of the complex from plasma, not iron turnover.
Primarily hepatic excretion via bile into feces; renal excretion accounts for <1% of the dose in patients with normal hepatic function.
Primarily eliminated via hepatobiliary and fecal routes as intact complex; renal excretion is minimal (<1%) for iron, but ferric carboxymaltose complex is not dialyzable. In patients with iron deficiency, ~50-60% of administered iron is incorporated into hemoglobin and red blood cells within 2-4 weeks; the remainder is stored as ferritin and hemosiderin. The carboxymaltose moiety is partially metabolized and excreted via urine and feces.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent